Molecules (Jan 2024)

Portable Mid-Infrared Spectroscopy Combined with Chemometrics to Diagnose Fibromyalgia and Other Rheumatologic Syndromes Using Rapid Volumetric Absorptive Microsampling

  • Shreya Madhav Nuguri,
  • Kevin V. Hackshaw,
  • Silvia de Lamo Castellvi,
  • Haona Bao,
  • Siyu Yao,
  • Rija Aziz,
  • Scott Selinger,
  • Zhanna Mikulik,
  • Lianbo Yu,
  • Michelle M. Osuna-Diaz,
  • Katherine R. Sebastian,
  • M. Monica Giusti,
  • Luis Rodriguez-Saona

DOI
https://doi.org/10.3390/molecules29020413
Journal volume & issue
Vol. 29, no. 2
p. 413

Abstract

Read online

The diagnostic criteria for fibromyalgia (FM) have relied heavily on subjective reports of experienced symptoms coupled with examination-based evidence of diffuse tenderness due to the lack of reliable biomarkers. Rheumatic disorders that are common causes of chronic pain such as rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and chronic low back pain are frequently found to be comorbid with FM. As a result, this can make the diagnosis of FM more challenging. We aim to develop a reliable classification algorithm using unique spectral profiles of portable FT-MIR that can be used as a real-time point-of-care device for the screening of FM. A novel volumetric absorptive microsampling (VAMS) technique ensured sample volume accuracies and minimized the variation introduced due to hematocrit-based bias. Blood samples from 337 subjects with different disorders (179 FM, 158 non-FM) collected with VAMS were analyzed. A semi-permeable membrane filtration approach was used to extract the blood samples, and spectral data were collected using a portable FT-MIR spectrometer. The OPLS-DA algorithm enabled the classification of the spectra into their corresponding classes with 84% accuracy, 83% sensitivity, and 85% specificity. The OPLS-DA regression plot indicated that spectral regions associated with amide bands and amino acids were responsible for discrimination patterns and can be potentially used as spectral biomarkers to differentiate FM and other rheumatic diseases.

Keywords